Search
selumetinib (AZD6244)
Contraindications:
- KRAS mutant advanced non-small cell lung cancer
* does not provides survival advantage over docetaxel alone
Mechanism of action:
- inhibits mek kinase-1 & mek kinase-2 [2]
General
small inhibitory antineoplastic agent (ib drug)
protein kinase inhibitor
Database Correlations
PUBCHEM cid=10127622
References
- Janne PA, van den Heuvel MM, Barlesi F et al
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and
Progression-Free Survival in Patients With KRAS-Mutant Advanced
Non-Small Cell Lung Cancer. The SELECT-1 Randomized Clinical
Trial.
JAMA. 2017;317(18):1844-1853. May 9, 2017
PMID: 28492898
http://jamanetwork.com/journals/jama/article-abstract/2625317
- PubChem: 10127622